JP2008535785A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535785A5 JP2008535785A5 JP2007557196A JP2007557196A JP2008535785A5 JP 2008535785 A5 JP2008535785 A5 JP 2008535785A5 JP 2007557196 A JP2007557196 A JP 2007557196A JP 2007557196 A JP2007557196 A JP 2007557196A JP 2008535785 A5 JP2008535785 A5 JP 2008535785A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- apoptosis
- composition according
- inducer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 230000006907 apoptotic process Effects 0.000 claims 13
- 239000000411 inducer Substances 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 230000003463 hyperproliferative effect Effects 0.000 claims 6
- ZAWXOCUFQSQDJS-VIFPVBQESA-N (3s)-8-hydroxy-3-methyl-3,4-dihydro-2h-benzo[a]anthracene-1,7,12-trione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C=CC1=C2C(=O)C[C@@H](C)C1 ZAWXOCUFQSQDJS-VIFPVBQESA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 101150099493 STAT3 gene Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000006882 induction of apoptosis Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000025084 cell cycle arrest Effects 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65659705P | 2005-02-25 | 2005-02-25 | |
| PCT/US2006/006637 WO2006091837A2 (en) | 2005-02-25 | 2006-02-24 | Small molecule inhibitors of stat3 and the uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535785A JP2008535785A (ja) | 2008-09-04 |
| JP2008535785A5 true JP2008535785A5 (enExample) | 2009-04-09 |
Family
ID=36928057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007557196A Withdrawn JP2008535785A (ja) | 2005-02-25 | 2006-02-24 | Ｓｔａｔ３の小分子阻害剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060247318A1 (enExample) |
| EP (1) | EP1853242A4 (enExample) |
| JP (1) | JP2008535785A (enExample) |
| CN (1) | CN101511179A (enExample) |
| AU (1) | AU2006216510A1 (enExample) |
| CA (1) | CA2599393A1 (enExample) |
| WO (1) | WO2006091837A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1934331A4 (en) | 2005-10-14 | 2009-01-21 | Musc Found For Res Dev | TARGETING PAX2 TO INDUCE CANCER TREATMENT AND TUMOR IMMUNITY INDUCED BY DEFB1 |
| US7857804B2 (en) * | 2006-09-01 | 2010-12-28 | Mccaffrey Timothy A | Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders |
| DK2120958T3 (da) * | 2006-12-06 | 2013-07-01 | Univ Central Florida Res Found | Stat3-inhibitor med anticancer-aktivitet og associerede fremgangsmåder |
| NZ578164A (en) * | 2007-01-16 | 2011-12-22 | Musc Found For Res Dev | Compositions and methods for diagnosing, treating, and preventing prostate conditions |
| WO2009032338A1 (en) * | 2007-09-09 | 2009-03-12 | University Of Florida Research Foundation | Apratoxin therapeutic agents: mechanism and methods of treatment |
| WO2009032351A1 (en) * | 2007-09-09 | 2009-03-12 | University Of Florida Research Foundation | Natural product agents, derivatives, and methods of treatment |
| JP5688840B2 (ja) | 2007-09-10 | 2015-03-25 | ボストン バイオメディカル， インコーポレイテッド | 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤 |
| US20090082470A1 (en) | 2007-09-24 | 2009-03-26 | Rafal Farjo | Stat3 inhibiting compositions and methods |
| US8450337B2 (en) | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
| LT2547205T (lt) | 2010-03-19 | 2024-06-10 | 1Globe Biomedical Co., Ltd. | Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai |
| KR101273747B1 (ko) * | 2010-09-09 | 2013-06-12 | 가톨릭대학교 산학협력단 | Ｓｔａ-21을 유효성분으로 함유하는 관절염의 예방 및 치료용 조성물 |
| CN102961374B (zh) * | 2012-12-12 | 2015-01-14 | 苏州大学 | 一种化合物的应用以及stat3抑制剂 |
| MX2015014181A (es) | 2013-04-09 | 2016-05-24 | Boston Biomedical Inc | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. |
| US11406707B2 (en) | 2014-02-10 | 2022-08-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | STAT3 phosphorylation during graft-versus-host disease |
| CN104693280A (zh) * | 2015-04-06 | 2015-06-10 | 苏州普罗达生物科技有限公司 | 信号传导及转录激活因子抑制多肽及其应用 |
| CN104725480A (zh) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | 一种信号传导及转录激活因子抑制多肽及其应用 |
| WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| CN106822898B (zh) * | 2017-02-17 | 2018-09-25 | 王晓华 | 靶向下调stat3基因表达在提高肺腺癌化疗敏感性方面的应用 |
| CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| CN109988125B (zh) * | 2018-10-25 | 2022-03-18 | 河南省锐达医药科技有限公司 | 一类新型苯甲酰苯胺化合物的制备方法和在肿瘤治疗上的应用 |
| CA3135802A1 (en) | 2019-04-05 | 2020-10-08 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
| WO2021232067A1 (en) * | 2020-05-15 | 2021-11-18 | Glg Pharma, Llc | Stats3 inhibition for treatment and prevention of human coronavirus infection |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4491588A (en) * | 1982-03-31 | 1985-01-01 | University Of Tennessee Research Corporation | Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics |
| WO2000044774A2 (en) * | 1999-01-27 | 2000-08-03 | The University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
-
2006
- 2006-02-24 CN CNA2006800123753A patent/CN101511179A/zh active Pending
- 2006-02-24 WO PCT/US2006/006637 patent/WO2006091837A2/en not_active Ceased
- 2006-02-24 JP JP2007557196A patent/JP2008535785A/ja not_active Withdrawn
- 2006-02-24 EP EP06736058A patent/EP1853242A4/en not_active Withdrawn
- 2006-02-24 US US11/361,149 patent/US20060247318A1/en not_active Abandoned
- 2006-02-24 CA CA002599393A patent/CA2599393A1/en not_active Abandoned
- 2006-02-24 AU AU2006216510A patent/AU2006216510A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535785A5 (enExample) | ||
| JP2011102304A5 (enExample) | ||
| JP2010535252A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2015523397A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2011068653A5 (enExample) | ||
| JP2014508752A5 (enExample) | ||
| JP2013526544A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2009138003A5 (enExample) | ||
| JP2009536191A5 (enExample) | ||
| RU2018109902A (ru) | Виды комбинированной терапии для лечения рака | |
| JP2016185995A5 (enExample) | ||
| JP2014533272A5 (enExample) | ||
| JP2018533560A5 (enExample) | ||
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2009506054A5 (enExample) | ||
| JP2009539994A5 (enExample) | ||
| JP2015527374A5 (enExample) | ||
| JP2009515901A5 (enExample) | ||
| JP2015519347A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2015508765A5 (enExample) | ||
| JP2009510165A5 (enExample) |